Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying thalidomide and fludarabine to see how well they
work compared to thalidomide alone in treating patients with hematologic cancer that has not
responded to previous treatment with fludarabine. Thalidomide may stop the growth of
hematologic cancer by stopping blood flow to the cancer. Combining thalidomide with
fludarabine may increase the effectiveness of chemotherapy by making cancer cells more
sensitive to the drug. It is not yet known whether thalidomide is more effective with or
without fludarabine for hematologic cancer.